“Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials”, J of Skin, vol. 8, no. 1, p. s304, Jan. 2024, doi: 10.25251/skin.8.supp.304.